To study the effect of Safuf-e-Zaranbad in patients with Non-Alcoholic Fatty Liver Disease

Clinical study of Non-Alcoholic Fatty Liver Disease with therapeutic evaluation of Safuf-e-Zaranbad (Curcuma zedoaria Rosc.) in its management: A Randomized, single blind, standard control study.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/03/050355

Enrollment

Registered

2023-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Safuf-e-Zaranbad: Safuf-e-Zaranbad (fine powder of Curcuma zedoaria Rosc.) is a Unani pharmacopeial medicine. Safuf-e-Zaranbad 2 capsules BD, each capsule weighing 500 mg shall be given

Eligibility

Inclusion criteria

Inclusion criteria: 1. USG documented grade 1 (mild) and grade 2 (moderate) non-alcoholic fatty liver disease. 2. Patients complaining dull ache or heaviness in the right upper quadrant (right hypochondrium). 3. Patients having symptoms like maliase and dyspepsia. 4. Irrespective of any gender. 5. Patients in the age group of 18-65 years. 6. Patients who have BMI 7. Those patients who are willing to give consent.

Exclusion criteria

Exclusion criteria: 1. Patients having USG documented fatty liver Grade 3 or above. 2. Patients with history of Alcoholic fatty liver disease. 3. Patients with history of chronic renal disorders. 4. Patients below the age of 18 and above the age of 65 years respectively. 5. Patients with BMI >34.9 kg/m2. 6. Patients priorly diagnosed with cholecystitis and cholelithiasis. 7. Patients having uncontrolled diabetes mellitus. 8. History of liver transplantation. 9. Lactating mother and pregnant women. 10. Patients already diagnosed with liver disorders other than non alcoholic fatty liver disease like Cirrhosis, viral hepatitis etc. 11. Patients who fail to give consent. 12. Patients taking lipid lowering drugs/ statins.

Design outcomes

Primary

Measure	Time frame
1. USG abdomen (Liver Span) 2. LFT (Sr. Bilirubin, SGOT, SGPT, ALP) 3. Lipid profile ( Sr. Triglycerides, Sr. Cholesterol, LDL, VLDL, HDL)Timepoint: 60 days	—

Secondary

Measure	Time frame
1.Maliase 2. Anorexia 3. Dull ache in the right hypochondrium 4. DyspepsiaTimepoint: 60 days	—

Countries

India

Contacts

Public ContactDr Shameem Ahmad Rather

Regional Research Institute of Unani Medicine (RRIUM)

shameem.rather.sr@gmail.com7889584083

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026